公开(公告)号：EP2609091B1

公开(公告)日：2014-11-26

申请号：EP11754617.6

申请日：2011-08-26

申请人： Lead Discovery Center GmbH ,  Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

发明人： SCHULTZ-FADEMRECHT, Carsten ,  KLEBL, Bert ,  CHOIDAS, Axel ,  KOCH, Uwe ,  EICKHOFF, Jan ,  WOLF, Alexander ,  ULLRICH, Axel

IPC分类号： C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D215/233 ,  A61K31/4709 ,  A61P35/00

CPC分类号： C07D401/12 ,  A61K31/47 ,  A61K31/495 ,  C07D215/233 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

公开(公告)号：EP2609091A1

公开(公告)日：2013-07-03

申请号：EP11754617.6

申请日：2011-08-26

申请人： Lead Discovery Center GmbH ,  Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

发明人： SCHULTZ-FADEMRECHT, Carsten ,  KLEBL, Bert ,  CHOIDAS, Axel ,  KOCH, Uwe ,  EICKHOFF, Jan ,  WOLF, Alexander ,  ULLRICH, Axel

IPC分类号： C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  A61K31/4709 ,  A61P35/00

CPC分类号： C07D401/12 ,  A61K31/47 ,  A61K31/495 ,  C07D215/233 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

摘要： The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides of general formula (I): and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.

公开(公告)号：EP2611919A2

公开(公告)日：2013-07-10

申请号：EP11760402.5

申请日：2011-09-05

申请人： Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

发明人： FALCENBERG, Mathias ,  ULLRICH, Axel

IPC分类号： C12N15/113 ,  A61K31/00 ,  A61K31/713 ,  A61P3/10

CPC分类号： A61K31/713 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/14 ,  C12Y207/11001 ,  C12Y207/11016 ,  C12Y207/1102

摘要： The present invention is related to compound capable of modulating the activity and/or expression of the protein kinases SCYL1, ADCK1, GRK5 and CSNK2A1, thereby enhancing the expression and/or release of insulin. The invention is further related to methods of identifying said compounds for the treatment of metabolic diseases. The invention is further related to methods of treatment of metabolic diseases, particularly diabetes mellitus type 2.

公开(公告)号：EP1207876B9

公开(公告)日：2012-04-18

申请号：EP00951521.4

申请日：2000-08-16

申请人： Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

发明人： ULLRICH, Axel ,  PRENZEL, Norbert ,  DAUB, Henrik ,  ZWICK-WALLASCH, Esther

IPC分类号： A61K31/38 ,  A61K31/16 ,  A61K38/55 ,  A61K38/05 ,  G01N33/50 ,  A61P11/06 ,  A61P31/00 ,  A61P35/00

CPC分类号： A61K38/55 ,  A61K31/00 ,  A61K31/381 ,  A61K38/05

摘要： The invention relates to agents and methods for growth-factor receptor activation by modulating the G-protein mediated signal transduction pathway.

公开(公告)号：EP1482964B1

公开(公告)日：2011-01-05

申请号：EP03714791.5

申请日：2003-03-07

申请人： Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

发明人： ULLRICH, Axel ,  SCHÄFER, Beatrix ,  FISCHER, Oliver ,  GSCHWIND, Andreas ,  LESERER, Michael

IPC分类号： A61K38/16 ,  A61K38/18 ,  A61K38/48 ,  C07K16/28 ,  A61K31/381 ,  A61K31/16

CPC分类号： A61K31/517 ,  A61K31/381 ,  A61K38/00 ,  A61K2039/505 ,  G01N33/5011 ,  G01N33/5029 ,  G01N33/5041

摘要： The present invention relates to the use of a compound which is capable of inhibiting activation of a growth factor receptor of the EGFR-family for the prevention or treatment of processes associated with increased G-protein mediated signal transduction.

公开(公告)号：EP1390525B8

公开(公告)日：2009-03-04

申请号：EP02748716.4

申请日：2002-05-23

申请人： Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

发明人： ULLRICH, Axel ,  STETÁK, Attila ,  KÉRI, György

IPC分类号： C12Q1/48 ,  G01N33/50 ,  G01N33/68

CPC分类号： G01N33/6875 ,  C12Q1/48 ,  G01N33/5005 ,  G01N2333/912 ,  G01N2500/00 ,  G01N2510/00

公开(公告)号：EP1049465B1

公开(公告)日：2006-10-11

申请号：EP99903669.2

申请日：1999-01-22

申请人： Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

发明人： ULLRICH, Axel ,  BANGE, Johannes ,  KNYAZEV, Pjotr

IPC分类号： A61K31/40 ,  C07K14/71 ,  C07K16/28 ,  C12N15/12 ,  C12Q1/68 ,  A61P35/00

CPC分类号： C07K14/71 ,  A61K38/00 ,  G01N33/574

摘要： The invention relates to the use of inhibitors for the treatment and/or prevention of diseases resulting from increased receptor tyrosine kinase activity, especially cancer. Use concerns particularly the inhibition or reduction of over-expression and/or altered activity of receptor tyrosine kinases (RKTs). Such changes in the activity of receptor tyrosine kinase may be triggered particularly by a mutation of the FGFR-4, which mutation is especially a point mutation in the transmembrane domain of FGFR-4 and leads to an exchange of a hydrophobic for a hydrophilic amino acid. The invention further relates to the use of an inhibitor directed against FGFR-4 for the treatment and/or prevention of cancer. The invention also relates to a mutated FGFR-4 causing overexpression and/or altered activity in cells. The invention finally relates to a DNA and RNA sequence of a mutated FGFR-4 molecule, a pharmaceutical composition comprising the inhibitor described above, and a diagnostic and screening method.

公开(公告)号：EP1641479A2

公开(公告)日：2006-04-05

申请号：EP04740660.8

申请日：2004-07-05

申请人： Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

发明人： ULLRICH, Axel ,  FISCHER, Oliver

IPC分类号： A61K38/00 ,  A61K48/00 ,  A61K39/395

CPC分类号： C12N15/1137 ,  A61K39/3955 ,  A61K45/06 ,  C12N2310/14 ,  A61K2300/00

摘要： The present invention relates to the inhibition of stress-induced receptor tyrosine kinase activity by inhibiting a ligand of said receptor tyrosine kinase, particularly an extracellular ligand.

公开(公告)号：EP1169054B1

公开(公告)日：2004-08-04

申请号：EP00921845.4

申请日：2000-04-06

申请人： Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

发明人： ULLRICH, Axel ,  MULLER, Thomas Sugen, Inc.

IPC分类号： A61K38/46 ,  A61K48/00 ,  C12Q1/68 ,  G01N33/573 ,  G01N33/50 ,  A61K31/404 ,  A61K31/517 ,  A61K31/498 ,  A61K31/00

CPC分类号： C12Y301/03048 ,  A61K31/00 ,  A61K31/404 ,  A61K31/498 ,  A61K31/517 ,  A61K38/00 ,  A61K48/00 ,  C12N9/16 ,  G01N33/573

摘要： The present invention relates to methods and products useful for the treatment of various epithelial cell migration diseases and disorders, and to methods useful for the identification of various products useful for the treatment of these diseases and disorders. In particular, methods for treatment using PTP LAR are described, as are methods for identifying compounds to modulate PTP LAR activity.

公开(公告)号：EP0690918A1

公开(公告)日：1996-01-10

申请号：EP94911950.0

申请日：1994-03-23

申请人： Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

发明人： MOLLER, Niels, P., H. ,  MOLLER, Karin, B. ,  ULLRICH, Axel

IPC分类号： G01N33 ,  A61K38 ,  A61K39 ,  A61P43 ,  C07K14 ,  C07K16 ,  C12N1 ,  C12N9 ,  C12N15 ,  C12P21 ,  C12Q1 ,  C12R1

CPC分类号： C12N9/16 ,  A61K38/00

摘要： A protein tyrosine phosphatase designated PTP-S31 and its subfamily are identified, as are nucleic acid molecules coding therefor. Included in this family are PTP-S31 proteins or glycoproteins having one, two, or three identified amino acid changes in previously defined consensus sequences in the catalytic phosphatase domains of known protein tyrosine phosphatases. The PTP-S31 proteins or glycoproteins may be produced by recombinant means. Antibodies to PTP-S31 proteins or glycoproteins and nucleic acid constructs coding therefor, and methods for screening molecules which can bind to PTP-S31 proteins or glycoproteins and inhibit or stimulate their enzymatic activity, are provided.